Anna N. Petrova

Anna N. Petrova

Auto-generated profile, based on publicly available information

Anna N. Petrova

National Medical Research Center for Hematology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
APAnna Petrova
Anna Petrova
ECEkaterina Chelysheva
Ekaterina Chelysheva
OSOleg Shukhov
Oleg Shukhov
ABAnastasiya Bykova
Anastasiya Bykova
INIrina Nemchenko
Irina Nemchenko
ATAnna Turkina
Anna Turkina

10 December 2020 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
ATA. G. Turkina
A. G. Turkina
APA. N. Petrova
A. N. Petrova
ECE. Yu. Chelysheva
E. Yu. Chelysheva
OSO. A. Shukhov
O. A. Shukhov
OTO. N. Tsyba
O. N. Tsyba
НЦН. Н. Цыба
Н. Н. Цыба
Introduction. The advent of tyrosine kinase inhibitors (TKIs) in clinical practice drastically improved prognosis in patients with chronic myeloid leukaemia (CML). Adverse events of the TKI therapy and its high financial burden warrant the trend to gradually abandon this treatment.Aim. To assess the results of CML patient monitoring after the withdrawal of TKI therapy.Patients and methods. This prospective study included 98 chronic phase CML patients satisfying the criteria: any receiving of TKI therapy for ≥3 years; deep molecular response (DMR, BCR-ABL ≤ 0.01 % IS) during ≥ 2 years. The withdrawal was followed by quantitative BCR-ABL estimation performed monthly for the first 6 months of the survey, bimonthly for 1 year and every 3 months from the second year onwards. Therapy was resumed at a loss of major molecular response (MMR, BCR-ABL ≥ 0.1 % IS).Results. The MMR loss upon the TKI withdrawal was observed in 48 (49 %) patients. Survival without MMR loss was 52 % past 24 months since withdrawal, with a median of 35 months (23–52). The duration of therapy, MR and the MR depth at the time of withdrawal significantly correlated with a conserved post-therapy MMR. Gender, age, a Sokal risk group, type and line of TKI therapy at withdrawal, and imatinib resistance in history were not observed to significantly impact molecular relapse-free remission. MMR was recovered in all 48 patients with TKI therapy resumed in molecular relapse. In 65 % of the patients, adverse therapy events observed during treatment completely resolved by 6 months of post-therapy monitoring. Musculoskeletal pain (withdrawal syndrome, WS) was reported in 42 % patients in the post-therapeutic period, which did not lead to TKI resumption. The WS development correlated with an elder age and longer therapy prior to withdrawal.Conclusion. Molecular relapse-free survival in CML patients with treatment-free remission (TFR) is comparable to other published evidence. Monitoring safety during TFR is attested by the lack of disease progression and MMR recovery upon TKI resumption in all patients.

20 October 2019 in Oncohematology
Verified
Journal Article
Open access
PDF file
APA. N. Petrova
A. N. Petrova
ECE. Yu. Chelysheva
E. Yu. Chelysheva
ATA. G. Turkina
A. G. Turkina
Tyrosine kinase inhibitors have radically changed the course of chronic myeloid leukemia, significantly increasing survival and reducing the risk of disease progression. Nearly 50–70 % of patients achieve a consistently low or undetectable level of minimal residual disease – a deep molecular response. The long-term tyrosine kinase inhibitors treatment in about one-third of patients is accompanied by toxicity which impairs the quality of life. Therefore, the safe treatment discontinuation is relevant. The results of clinical trials have shown 40-60% possibility of maintaining treatment-free remission in patients with long-term deep molecular respons; however, all patients with molecular relapse regain molecular remission after the resumption of tyrosine kinase inhibitors therapy. Currently, clinical and biological factors associated with maintaining treatment-free remission are being studied. It is assumed that cessation of tyrosine kinase inhibitors therapy can improve the quality of life, but approximately 30 % of patients are reporting musculoskeletal pain – so called “withdrawal syndrome” – that begins or worsens after stopping tyrosine kinase inhibitors therapy. The mechanisms for the development of this phenomenon are currently unclear. Thus, many aspects concerning treatment-free remission require to be studied, which determines the importance of clinical trials in this area.

22 May 2025 in Oncohematology
Verified
Journal Article
Open access
PDF file
APA. N. Petrova
A. N. Petrova
ELElza Lomaia
Elza Lomaia
EME. V. Morozova
E. V. Morozova
OSO. A. Shukhov
O. A. Shukhov
ECE. Yu. Chelysheva
E. Yu. Chelysheva
ЮВЮ. Ю. Власова
Ю. Ю. Власова
Background. The most common mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is point mutations in the BCR::ABL1 gene. Of particular importance is the T315I mutation, which causes insensitivity of leukemia cells to all ATp-competitive TKIs: imatinib and 2nd generation TKIs. Asciminib is the first drug of the STAMp inhibitor class that specifically interacts with the myristoyl-binding active site of the bCR::AbL1 molecule. In a phase I clinical trial, asciminib at a dose of 200 mg twice daily showed efficacy in the treatment of chronic phase (Cp) CML patients with T315I mutation. There are no data on the efficacy of asciminib therapy in patients with T315I mutation and additional chromosomal abnormalities (ACA) or advanced disease. The Russian part of the managed access program (MAp) has accumulated its own experience of using asciminib in CML patients with T315I mutation, including those with ACA and history of progression to the acceleration phase / blast crisis.Aim. To analyze the 3-year results of asciminib therapy as part of MAp in CML patients with T315I mutation.Materials and methods. In the MAp program to asciminib between October 2019 and January 2022 were included 26 CML patients with T315I mutation who were ineffective or intolerant to ATp-competitive TKIs therapy. Asciminib was administered at a dose of 200 mg twice daily. The efficacy and tolerability of asciminib therapy were assessed in accordance with national clinical guidelines and the 2020 European LeukemiaNet guidelines.At the time of asciminib therapy initiation, 19 (73 %) patients had Cp. four (15 %) patients had a history of acceleration phase (n = 3) and blast crisis (n = 1). four (15 %) patients had ACA immediately before the start of asciminib therapy, including a patient with a history of blast crisis. To analyze the asciminib therapy results, patients with a history of progression and / or ACA were combined into one group: 2Cp / Cp ACA+ (n = 7). More than half of patients (54 %) had previously received ponatinib.Results. The median duration of asciminib therapy was 31.6 (3.3–50) months. Of the 26 patients, 25 (96 %) are alive, one patient in the 2Cp / Cp ACA+ group died from progression of CML to myeloid blast crisis. In the total group, 14 patients (54 %) continued asciminib therapy, 12 (46 %) – discontinued treatment: most patients due to treatment failure (n = 9 (75 %)). In 3 patients (25 %), the reason for treatment discontinuation was allogeneic hematopoietic stem cell transplantation (all three achieved a complete cytogenetic response with asciminib therapy). No patients discontinued treatment due to toxicity. No new mutations, including asciminib resistance mutations, were detected during therapy.Progression-free survival and survival without therapy discontinuation at 3 years of follow-up in the total group were 92 and 58 %, respectively. when analyzing the Cp and 2Cp / Cp ACA+ groups, progression-free survival at 3 years of asciminib therapy was comparable. There was a trend toward decreased survival without therapy discontinuation in 2Cp / Cp ACA+ group (28 %) versus Cp group (63 %) (p = 0.0856).The probability of achieving a complete cytogenetic response / molecular response MR2 in all patients with T315I mutation by the 3rd year of asciminib treatment was 59 %, in the Cp and 2Cp / Cp ACA+ groups – 47 and 80 %, respectively; no significant difference were found between the groups (p = 0.08). The probability of achieving a major molecular response (MMR) in the total group by the 3rd year of asciminib treatment was 42 %; the probability of achieving MMR in the Cp and 2Cp / Cp ACA+ groups was 44 and 33 %, respectively; no significant difference were found between the groups (p = 0.6).In univariate analysis, significant favorable factors for achieving MMR were the molecular response at the start of asciminib therapy ≤10 %, the best molecular response in prior TKI therapy ≤1 %, and the absence of prior ponatinib treatment. In multivariate analysis, a history of ponatinib therapy was an independent significant factor for achieving MMR with asciminib therapy (p = 0.02; hazard ratio 12.08).Conclusion. The therapy results of patients in initially unfavorable 2Cp / Cp ACA+ group were comparable with Cp group in terms of both survival rates and probability of achieving responses. However, given the small number of patients in our cohort, the asciminib efficacy in patients with T315I+ CML with ACA and a history of progression requires further investigation. A factor that significantly reduced the probability of achieving MMR during asciminib treatment was a history of ponatinib therapy.

1 October 2024 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
МГМаргарита Анатольевна Гурьянова
Маргарита Анатольевна Гурьянова
VKV. I. Kazey
V. I. Kazey
OSO. A. Shukhov
O. A. Shukhov
ECE. Yu. Chelysheva
E. Yu. Chelysheva
ANA. G. Nikiforova
A. G. Nikiforova
ATA. G. Turkina
A. G. Turkina
AIM. To measure the trough and maximum plasma concentrations of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients on standard and reduced doses of the drugs, to evaluate the impact of TKI plasma concentration on the loss of major/deep molecular response (MR) after dose reduction and the impact of TKI plasma concentration on drug toxicity changes. MATERIALS & METHODS. The trial enrolled 46 imatinib and 16 nilotinib recipients. The trough (Сtrough) and maximum (Cmax) TKI plasma concentrations were measured. On imatinib/nilotinib therapy, Ctrough was analyzed in 104/22 and Cmax was analyzed in 63/15 plasma samples, respectively. RESULTS. The mean plasma imatinib Ctrough values on daily 400 mg, 300 mg, and 200 mg of the drug were 1092 ± 346 ng/mL, 809.5 ± 313.0 ng/mL, and 570.9 ± 280.0 ng/mL, respectively. The mean plasma imatinib Cmax on daily 300 mg and 200 mg were 1944 ± 577 ng/mL and 1233.4 ± 44.0 ng/mL, respectively. In the group of patients without deep MR-loss, on daily 300 mg and 200 mg imatinib, the mean plasma Ctrough values were 773.5 ± 303.0 ng/mL and 586.3 ± 308.0 ng/mL, and the mean Cmax values were 1866.5 ± 532.0 ng/mL and 1283.7 ± 481.0 ng/mL, respectively. In the group of patients with deep MR-loss, on daily 300 mg and 200 mg imatinib, the mean plasma Ctrough values were 774.8 ± 553.0 ng/mL and 490.6 ± 175.0 ng/mL, and the mean Cmax values were 2246 ± 1171 ng/mL and 1124.7 ± 281.0 ng/mL, respectively (p > 0.05). The mean plasma imatinib Ctrough values on daily 400 mg, 300 mg, and 200 mg of the drug in the group of patients with drug toxicity were 1120.6 ± 303.0 ng/mL, whereas in the group without adverse effects these values were 998.4 ± 402.0 ng/mL (p = 0.09). The mean nilotinib Ctrough values on daily 600 mg, 400 mg, and 200 mg were 651.4 ± 397.0 ng/mL, 468.7 ± 220.0 ng/mL, and 376.7 ± 151.0 ng/mL, respectively. The mean nilotinib Cmax values on daily 400 mg and 200 mg were 655.3 ± 189.0 ng/mL and 628 ± 293 ng/mL, respectively. CONCLUSION. This clinical trial yielded differences in plasma imatinib Ctrough and Cmax values in CML patients treated with standard and reduced doses of the drug, which turned out to be significant (p < 0.05). No significant differences in plasma nilotinib Ctrough and Cmax were identified. This trial revealed no significant differences in plasma imatinib Ctrough and Cmax on daily 400 mg and 300 mg of the drug in the groups of patients with and without adverse events. However, while dividing plasma imatinib Ctrough values during the period of 400 mg per day administration into 4 quartiles (Q1 and Q4 included patients with the lowest and the highest Ctrough values, respectively), the proportion of patients with drug toxicity appeared to be the highest in Q4 and accounted for 90 %.

11 May 2023 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
APA. N. Petrova
A. N. Petrova
ECE. Yu. Chelysheva
E. Yu. Chelysheva
INI. S. Nemchenko
I. S. Nemchenko
ABA. V. Bykova
A. V. Bykova
MGM. A. Gurianova
M. A. Gurianova
ATA. G. Turkina
A. G. Turkina
   Introduction. The option of observation without therapy with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients is already included in Russian and international clinical guidelines. Evaluation of long-term follow-up results of treatment free remission (TFR) in CML patients is relevant for the introduction of this approach into routine clinical practice.   Aim — to demonstrate the outcomes in a long-term follow-up of CML patients who discontinued TKI therapy in the RU-SKI trial.   Patients and methods. The prospective study included 98 CML patients with TKI therapy duration ≥ 3 years and a deep molecular response (DMR, BCR::ABL1 ≤ 0.01 %) duration ≥ 2 years. TKI therapy was resumed with the loss of a major MR (MMR, BCR::ABL1 > 0,1 %).   Results. Median time of follow-up after TKI discontinuation was 64 months (range of 51–86 months). Survival without MMR loss at 3 and 5 years after TKI discontinuation was 51 % (CI 41–61 %) and 46 % (CI 36–57 %) respectively. From 3 to 5 years of follow-up without therapy, the loss of MMR occurred in 2 (4 %) patients. There was no MMR loss observed after 5 years of follow-up. In patients with first and second treatment discontinuation, survival without MMR loss was 50 % versus 12,5 %(р = 0,039). All 50 patients with molecular relapses regained MMR and MR4 after TKI therapy resumption. BCR::ABL1 level fluctuations 0,01–0,1 % were in 62 % (n = 29) patients, who were in TFR at the time of analysis. Loss of MR4 was observed in 38 (42 %) from 90 patients with first TKI discontinuation. Survival without MMR loss from MO4 loss was 24 % at 5 years after TKI discontinuation. Loss of MO4 in the first 3 months after TKI cessation was associated with a high probability of further MMR loss (8 % versus 54 % in patients with loss of MO4 for > 3 months, p = 0.00015).   Conclusion. The low frequency of late relapses (4 % after 3 years of follow-up) and the possibility of long-term persistence of minimal residual disease (MRD) after discontinuation of therapy determine the need to optimize the timing of molecular monitoring, taking into account the MRD status of patients.